Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study.
Sweden
cost of illness
late-stage Parkinson's disease
quality of life
Journal
Acta neurologica Scandinavica
ISSN: 1600-0404
Titre abrégé: Acta Neurol Scand
Pays: Denmark
ID NLM: 0370336
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
revised:
28
02
2022
received:
24
11
2021
accepted:
03
03
2022
pubmed:
22
3
2022
medline:
6
5
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce. First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures. The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016. In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs. Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients' HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Few studies have investigated the health-related quality of life (HRQoL), resource use and costs in patients with late-stage Parkinson's disease (PD), and data from the Swedish setting are scarce.
OBJECTIVES
OBJECTIVE
First, we analyse the HRQoL in late-stage PD in Sweden. Second, we analyse the resource use and costs per severity level. Third, we analyse the relationship between costs and physician- and patient reported-outcome measures.
MATERIALS AND METHODS
METHODS
The study was based on Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study. The costs of healthcare contacts, drugs, formal and informal care, and productivity loss were collected over three months. Assessments at baseline were used for outcomes (EQ-5D, Hoehn and Yahr (H&Y), Schwab and England Scale, Unified Parkinson's Disease Rating Scale subscales (UPDRS) and Non-Motor Symptoms Scale (NMSS)). Costs were estimated in € 2016.
RESULTS
RESULTS
In total, 106 patients were included. The mean EQ-5D score in the total group was 0.24 (±0.33). The mean total cost excluding informal care per patient in the three-month period was approximately €14,097 (BCa 95% CI €12,007 and €16,039). Professional care accounted for the largest share (75 percent) of the total costs. The EQ-5D, H&Y, Schwab and England Scale, and NMSS were statistically significant predicting factors for total costs.
CONCLUSION
CONCLUSIONS
Patients with late-stage PD are a vulnerable patient group that is costly to society and the impairment in patients' HRQoL is immense. Thus, healthcare decision-makers should optimize the organization and provision of healthcare for these patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
743-752Subventions
Organisme : European Commission
Informations de copyright
© 2022 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
Références
Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord. 2000;15:1112-1118. doi:10.1002/1531-8257(200011)15:6<1112:aid-mds1008>3.0.co;2-a
Kalampokini S, Hommel ALAJ, Lorenzl S, et al. Caregiver Burden in Late-Stage Parkinsonism and its associations. J Geriatr Psychiatry Neurol. 2020;35:110-120. doi:10.1177/0891988720968263
Hely MA, Morris JGL, Reid WGJ, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190-199. doi:10.1002/mds.20324
Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord. 2002;17:1213-1220. doi:10.1002/mds.10262
von Campenhausen S, Winter Y, Rodrigues e Silva A, et al. Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol. 2011;21:180-191. doi:10.1016/j.euroneuro.2010.08.002
Spottke AE, Reuter M, Machat O, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics. 2005;23:817-836. doi:10.2165/00019053-200523080-00007
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease patients in Sweden. Acta Neurol Scand. 2012;125:142-147. doi:10.1111/j.1600-0404.2011.01517.x
Weerkamp NJ, Zuidema SU, Tissingh G, et al. Motor profile and drug treatment of nursing home residents with Parkinson's disease. J Am Geriatr Soc. 2012;60:2277-2282. doi:10.1111/jgs.12027
Findley LJ, Wood E, Lowin J, Roeder C, Bergman A, Schifflers M. The economic burden of advanced Parkinson’s disease: an analysis of a UK patient dataset. J Med Econ. 2011;14:130-139. doi:10.3111/13696998.2010.551164
Balzer-Geldsetzer M, Ferreira J, Odin P, et al. Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurol. 2018;18:185. doi:10.1186/s12883-018-1184-3
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442. doi:10.1212/wnl.17.5.427
Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020-1028. doi:10.1002/mds.20213
Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. E & S Livingston; 1969: 152-157.
Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. 2007;22:1901-1911. doi:10.1002/mds.21596
EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208. doi:10.1016/0168-8510(90)90421-9
Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095-1108. doi:10.1097/00005650-199711000-00002
Welfare NBoHa. Statistikdatabasen. 2020; Accessed July 29, 2020. https://sdb.socialstyrelsen.se/if_par/resultat.aspx
Southern Healthcare Region. Regionala priser och ersättningar för Södra sjukvårdsregionen; 2016. https://sodrasjukvardsregionen.se/foregaende-ar-prislista-2016/. Accessed 11 May 2021.
Västra sjukvårdsregionen-Samverkansnämnden. Utomlänspriser 2016. 2015.
kolada.se. Lunds kommun 2016. 2016, 2.-0.-2. www.kolada.se
Statistics Sweden. Statistikdatabasen- Arbetsinkomst för helårs- och heltidsanställda personer 20-64 år 2016, 2.-0.-2. https://www.statistikdatabasen.scb.se. Accessed 11 May 2021.
Ekonomifakta, Sociala avgifter över tid, 2016. http://www.ekonomifakta.se/Fakta/Skatter/Skatt-pa-arbete/Sociala-avgifter-over-tid/. Accessed 11 May 2021.
Burström K, Johannesson M, Diderichsen F. Swedish population health-related quality of life results using the EQ-5D. Qual Life Res. 2001;10:621-635. doi:10.1023/a:1013171831202
World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-926.
Hjalte F, Norlin JM, Kellerborg K, Odin P. Parkinson's disease in Sweden-resource use and costs by severity. Acta Neurol Scand. 2021;144:592-599. doi:10.1111/ane.13502
Chandler C, Alvarez P, Folse HJ, Ward A. PND125 - the association between utilities and disease severity for Parkinson’s disease: a systematic literature review. Value Health. 2018;21:S350. doi:10.1016/j.jval.2018.09.2090
Norlin JM, Kellerborg K, Odin P. Patient utilities in health states based on Hoehn and Yahr and off-time in Parkinson’s disease: a Swedish register-based study in 1823 observations. Pharmacoeconomics. 2021;39(10):1141-1149. doi:10.1007/s40273-021-01056-z
Tamás G, Gulácsi L, Bereczki D, et al. Quality of life and costs in Parkinson's disease: a cross sectional study in Hungary. PLoS One. 2014;9:e107704. doi:10.1371/journal.pone.0107704
Rosqvist K, Odin P, Hagell P, Iwarsson S, Nilsson MH, Storch A. Dopaminergic effect on non-motor symptoms in late stage Parkinson's disease. J Parkinsons Dis. 2018;8:409-420. doi:10.3233/JPD-181380
Rosqvist K, Odin P, Lorenzl S, et al. Factors associated with health-related quality of life in late-stage Parkinson's disease. Mov Disord Clin Pract. 2021;8:563-570. doi:10.1002/mdc3.13186